Private
Recognizing the delays that have plagued low-income countries at nearly every aspect of the COVID-19 pandemic, the Bill & Melinda Gates Foundation announced this week a pledge of up to $120 million to accelerate access to the antiviral drug molnupiravir among low-income nations.
Molnupiravir is... Read More »
Results arrived this week for a Phase 3 trial of Valneva SE’s COVID-19 vaccine candidate, VLA2001, and they revealed neutralizing antibody activity greater than 95 percent, along with broad T-cell responses and significant tolerability.
It was reported that the inactivated, adjuvanted vaccine... Read More »
Lockheed Martin has secured a $9,672,781 Army Project Agreement to continue developing the Terrestrial Layer System (TLS) program for the branch's tactical vehicles.
The action via the Army's Consortium Management Group (CMG)/Consortium for Command, Control, and Communications in Cyberspace (C5)... Read More »
The National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative split $77.7 million among 12 new contract awards last week for potential, rapid SARS-CoV-2 diagnostic tests.
Part of the RADx Tech program, which gathered a panel of technical, regulatory and business... Read More »
Food and Drug Administration (FDA) officials said the agency will conduct a Nov. 30 meeting via its Antimicrobial Drugs Advisory Committee (AMDAC) to discuss a COVID-19 oral treatment.
The FDA indicated the effort would focus on Merck and Ridgeback’s request for an emergency use authorization... Read More »
Following two successful Phase 3 trials of more than 6,000 patients, the United States Food and Drug Administration (FDA) last week accepted the Regeneron Pharmaceuticals, Inc. anti-COVID-19 cocktail known as REGEN-COV for priority review.
REGEN-COV is a mix of the antibodies casirivimab and... Read More »
The all-star team of government officials, scientists and industry executives who tackled COVID-19 made great strides in the development of an effective vaccine against the novel virus, but that is no guarantee that the United States will be ready for the next pandemic that rears its head, speakers... Read More »
The first participant in a new trial phase recently received a dose of a vaccine candidate against chikungunya disease that is being developed by Emergent BioSolutions Inc.
“Emergent has achieved a major milestone as we begin our phase 3 study for our single-dose chikungunya vaccine... Read More »
Shortly after the terrorist events of Sept. 11, 2001, letters containing deadly anthrax spores arrived at locations across the country, killing five Americans and sickening 17 others. Twenty years after these incidents, considered the worst biological attacks in U.S. history, the federal government... Read More »
The threat detection and security screening technology firm Smiths Detection recently confirmed its BioFlash air sampler detects a series of SARS-CoV-2 variants.
Officials said the detected variants include the Alpha variant, Beta variant, Gamma variant, the Kappa variant and the Delta and Delta... Read More »
In a letter to high-ranking members of the Biden Administration’s COVID-19 response efforts, three Democratic senators and representatives this week urged a cautious review of the United States Health and Human Services (HHS) contract with Moderna, Inc. and called for efforts to expand global... Read More »
Through exercise of an option with Moderna, Inc., Gavi, the Vaccine Alliance will purchase another 176.5 million doses of the company’s COVID-19 vaccine in an effort to help low income countries over the course of the next year, through the COVAX Facility.
With this purchase, COVAX will have... Read More »
According to the latest annual report from the global nonprofit partnership CARB-X, at the close of its fifth fiscal year it has provided as much as $361 million to 92 projects seeking solutions to antibiotic resistant bacteria, gathered new partners under its umbrella and continually grown its... Read More »
Moderna officials said the company is slated to build a messenger RNA (mRNA) facility in Africa, producing up to 500 million vaccine doses annually at the 50 microgram dose level.
“Since Moderna’s founding in 2010, our mission has been to make a transformative impact on human lives through... Read More »
VE303, an oral treatment developed by Vedanta Biosciences for patients at high risk of recurrent C. difficile infections (CDI), will get a Phase 3 clinical evaluation trial, thanks to support from the Biomedical Advanced Research and Development Authority (BARDA).
Support from the U.S. government... Read More »
The World Health Organization (WHO) has recommended the first vaccine to treat malaria in children, a mosquito-borne disease that kills more than 260,000 children under the age of five annually in sub-Saharan Africa, in what public health officials have called a historic development.
“The... Read More »
Although its COVID-19 vaccine was never authorized for use in the United States, AstraZeneca submitted a request with the U.S. Food and Drug Administration (FDA) this week seeking emergency use authorization (EUA) for its long-acting antibody (LAAB) combination for use against symptomatic... Read More »
Ending speculation, Johnson & Johnson (J&J) this week officially submitted data to the United States Food and Drug Administration (FDA) to request emergency use authorization (EUA) for a booster version of its COVID-19 vaccine among patients at least 18 years old.
Recent data showed that the J&J... Read More »
The over-the-counter (OTC) ACON Laboratories Flowflex COVID-19 Home Test has received Food and Drug Administration (FDA) emergency use authorization.
FDA officials said the approval serves as testament to the agency's commitment to increasing the availability of accurate and reliable OTC tests to... Read More »
In a new report issued this week, the Bipartisan Commission on Biodefense warned that the United States needs to protect infrastructure, share and secure information, and maintain public works and services, or risk further devastation from biological threats like COVID-19.
The report was titled... Read More »
Results of an interim analysis for the Phase 3 trial of molnupiravir, an investigational oral antiviral for COVID-19 produced by Merck and Ridgeback Biotherapeutics, showed the drug capable of cutting hospitalization or death risk approximately in half.
For the purposes of the trial, over the... Read More »
Safe and effective: this was the verdict of Phase 3 trial results for Regeneron Pharmaceuticals, Inc.’s REGEN-COV COVID-19 treatment, as published in the New England Journal of Medicine earlier this week.
That trial reportedly met both its primary and secondary endpoints, inducing... Read More »
An ages-old issue may be on the road to modern solutions, thanks to a new collaboration between the Biomedical Advanced Research and Development Authority (BARDA) and Clarivate that will use advanced computer methods to find therapeutics for use on chlorine and sulfur mustard-caused... Read More »
Raytheon Missiles & Defense and Northrop Grumman personnel are touting the successful completion of the first flight test of a scramjet-powered Hypersonic Air-breathing Weapon Concept (HAWC).
The companies are slated to produce a prototype to the Department of Defense for the Defense... Read More »
Earlier this month, the Nuclear Threat Initiative gathered 100 international experts on biosafety for the 2021 Virtual Global Biosecurity Dialogue (GBD), the latest in an annual series of discussions on how best to maintain attention on and advance biosecurity across the world.
COVID-19 loomed... Read More »
The World Health Organization (WHO) approved Regeneron Pharmaceuticals’ drug cocktail of casirivimab and imdevimab for use on COVID-19 patients last week, but that endorsement came with a caveat: it urged lower prices, patent releases and equitable distribution.
The Regeneron antibody... Read More »
At the United States-hosted Global COVID-19 Summit last week, world leaders recommitted to guaranteeing equitable vaccine access for all countries through COVAX, and pledged a mix of funds, doses and supply chain aid to ensure it.
“Science has made huge progress in the fight to save lives,... Read More »
A cooperative effort was enacted against zoonotic diseases this week, with an agreement reached between the International Atomic Energy Agency (IAEA) and France’s Preventing Zoonotic Disease Emergence (PREZODE) initiative.
Members of the IAEA’s Zoonotic Disease Integrated Action (ZODIAC)... Read More »
Curtiss-Wright Corporation officials said the firm has secured Navy contracts totaling $100 million to provide pumps for the military branch's Virginia-class submarine, Columbia-class submarine and Ford-class aircraft carrier programs.
“Curtiss-Wright is proud to have been awarded these... Read More »
The Mexican government approved biotechnology company INOVIO to begin a Phase 3 efficacy trial of its COVID-19 DNA vaccine candidate, INO-4800, this week alongside its partner Advaccine Biopharmaceuticals Suzhou Co., Ltd.
This Mexican trial is part of a larger, worldwide Phase 2/3 trial known as... Read More »
The Infectious Diseases Society of America (IDSA) and its HIV Medicine Association (HIVMA) announced that it supports the Biden Administration’s movements in making the COVID-19 vaccines accessible around the world, but said more could be done to achieve vaccine equity.
In a letter to the... Read More »
While falling short of the full authorization Pfizer Inc. and BioNTech SE have clamored for, the United States Food and Drug Administration (FDA) has amended existing emergency use authorization (EUA) for the companies’ COVID-19 vaccine to allow a single booster dose for certain... Read More »
The Nuclear Threat Initiative (NTI) commended President Joe Biden for hosting a Global COVID-19 Summit and encouraged those participating in the summit to commit to stemming the impacts of the pandemic around the world.
NTI -- a nonprofit, nonpartisan global security organization focused on... Read More »
Tacking onto President Joe Biden’s call to make the United States an arsenal of vaccines for the world, Pfizer Inc. and BioNTech SE agreed to expand an arrangement with the U.S. government and provide another 500 million doses of their COVID-19 vaccine for low and lower-middle-income... Read More »
As the CEO of American PAPR, a Brooklyn-based company that manufactures American-made personal protective equipment, Giles Kyser has hired lobbyists to make the case that the federal government should procure medical equipment whose raw materials are sourced and assembled in the United States.... Read More »
